The results presented above clearly demonstrate that disruption of the htrA gene can be implemented for the development of a safe live-attenuated anthrax vaccine without compromising the protective characteristic exhibited by the parental Sterne vaccine strain. The gene discussed is HTRA1; the disease is anthrax infection.